Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTK | P29376 | 2/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.55 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.55 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | PRKACA | P17612 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | GRK5 | P34947 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
| ▸ | MST1R | Q04912 | 1/20 | 0.43 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071816 | 0.88 | BRD4 (0.45) | LTKALKDYRK1BCHEK1DAPK3 | |
| SCHEMBL4241887 | 0.87 | LTK (0.41) | LTKALKDYRK1BCHEK1DAPK3 | |
| SCHEMBL4060549 | 0.86 | MAPK9 (0.46) | LTKALKDYRK1BCHEK1DAPK3 | |
| SCHEMBL4239547 | 0.86 | LTK (0.40) | LTKALKDYRK1BCHEK1DAPK3 | |
| SCHEMBL4061377 | 0.81 | CYP11B1 (0.44) | LTKALKDYRK1BCHEK1RET | |
| SCHEMBL4065325 | 0.80 | LTK (0.39) | LTKALKDYRK1BCHEK1DAPK3 | |
| SCHEMBL4237750 | 0.78 | TP53 (0.40) | LTKALKDYRK1BROCK1RET | |
| SCHEMBL4070659 | 0.78 | CHEK1 (0.46) | CHEK1TYRO3AKT1AKT2GSK3A | |
| SCHEMBL4061355 | 0.76 | PDE5A (0.38) | LTKALKDYRK1BCHEK1DAPK3 | |
| SCHEMBL4504820 | 0.76 | PDE5A (0.48) | LTKALKDYRK1BCHEK1DAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501435-B2 | Inhibitors of checkpoint kinases | MERCK & CO., INC. (US) | 2009-03-10 | — | — | US | claimed |
| EP-2013212-A1 | TRIAZOLOQUINAZOLINONE DERIVATIVES AS INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2009-01-14 | — | — | EP | claimed |
| WO-2007127138-A1 | TRIAZOLOQUINAZOLINONE DERIVATIVES AS INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | claimed |
| US-20070254879-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | claimed |
| US-7501435-B2 | Inhibitors of checkpoint kinases | MERCK & CO., INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501435-B2 | Inhibitors of checkpoint kinases | MERCK & CO., INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501435-B2 | Inhibitors of checkpoint kinases | MERCK & CO., INC. (US) | 2009-03-10 | — | — | US | disclosed |
| EP-2013212-A1 | TRIAZOLOQUINAZOLINONE DERIVATIVES AS INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007127138-A1 | TRIAZOLOQUINAZOLINONE DERIVATIVES AS INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070254879-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | disclosed |
| US-20070254879-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | disclosed |
| US-20070254879-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254879-A1 | Inhibitors of checkpoint kinases | CHEK1, CHEK2, PLK1 | LTK 488/4885ALK 1292/4885DYRK1B 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.